Development of molecular and pharmacological switches for chimeric antigen receptor T cells
Abstract The use of chimeric antigen receptor (CAR) T cell technology as a therapeutic strategy for the treatment blood-born human cancers has delivered outstanding clinical efficacy. However, this treatment modality can also be associated with serious adverse events in the form of cytokine release...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2019-11-01
|
| Series: | Experimental Hematology & Oncology |
| Online Access: | http://link.springer.com/article/10.1186/s40164-019-0151-z |